Scholar Rock Holding Corporation (SRRK)
NASDAQ: SRRK · Real-Time Price · USD
30.97
-1.88 (-5.71%)
Mar 31, 2025, 9:49 AM EDT - Market open

Company Description

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.

Its transforming growth factor beta (TGFβ) superfamily biology, its novel understanding of the molecular mechanisms of growth factor activation enabled us to develop a proprietary platform for development of monoclonal antibodies that locally and selectively target the precursor.

The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.

It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia.

Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Scholar Rock Holding Corporation
Scholar Rock Holding logo
Country United States
Founded 2012
IPO Date May 24, 2018
Industry Biotechnology
Sector Healthcare
Employees 128
CEO Jay Backstrom

Contact Details

Address:
301 Binney Street, 3rd Floor
Cambridge, Massachusetts 02142
United States
Phone 857 259 3860
Website scholarrock.com

Stock Details

Ticker Symbol SRRK
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001727196
CUSIP Number 80706P103
ISIN Number US80706P1030
Employer ID 82-3750435
SIC Code 2836

Key Executives

Name Position
Dr. Jay Thomas Backstrom M.D., M.P.H. President, Chief Executive Officer and Director
Edward H. Myles MBA Senior Advisor
Tracey M. Sacco M.B.A. Chief Commercial Officer
Ryan Iarrobino Senior Vice President of Clinical Development and Operations
Dr. Jing L. Marantz M.B.A., M.D., Ph.D. Chief Medical Officer
Beth Shafer Ph.D. Chief Business Officer
Lisa Wyman Chief Technical and Quality Officer

Latest SEC Filings

Date Type Title
Mar 24, 2025 144 Filing
Mar 21, 2025 8-K Current Report
Mar 17, 2025 144 Filing
Mar 10, 2025 144 Filing
Feb 27, 2025 S-8 Securities to be offered to employees in employee benefit plans
Feb 27, 2025 10-K Annual Report
Feb 27, 2025 8-K Current Report
Feb 19, 2025 144 Filing
Feb 14, 2025 SCHEDULE 13G/A Filing
Feb 12, 2025 SCHEDULE 13G/A Filing